Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.62
ROSG's Cash-to-Debt is ranked lower than
57% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. ROSG: 1.62 )
Ranked among companies with meaningful Cash-to-Debt only.
ROSG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.77  Med: 62.38 Max: No Debt
Current: 1.62
Equity-to-Asset 0.37
ROSG's Equity-to-Asset is ranked lower than
80% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ROSG: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
ROSG' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.27  Med: 0.7 Max: 0.95
Current: 0.37
-0.27
0.95
Debt-to-Equity 0.86
ROSG's Debt-to-Equity is ranked lower than
83% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. ROSG: 0.86 )
Ranked among companies with meaningful Debt-to-Equity only.
ROSG' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.76  Med: 0.01 Max: 0.86
Current: 0.86
-2.76
0.86
Piotroski F-Score: 2
Altman Z-Score: -21.16
WACC vs ROIC
3.52%
-364.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -169.64
ROSG's Operating Margin % is ranked lower than
78% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. ROSG: -169.64 )
Ranked among companies with meaningful Operating Margin % only.
ROSG' s Operating Margin % Range Over the Past 10 Years
Min: -9864.67  Med: -3704.25 Max: -169.63
Current: -169.64
-9864.67
-169.63
Net Margin % -175.80
ROSG's Net Margin % is ranked lower than
80% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. ROSG: -175.80 )
Ranked among companies with meaningful Net Margin % only.
ROSG' s Net Margin % Range Over the Past 10 Years
Min: -11003.33  Med: -4193.47 Max: -175.8
Current: -175.8
-11003.33
-175.8
ROE % -132.15
ROSG's ROE % is ranked lower than
90% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. ROSG: -132.15 )
Ranked among companies with meaningful ROE % only.
ROSG' s ROE % Range Over the Past 10 Years
Min: -545.27  Med: -84.49 Max: -47.3
Current: -132.15
-545.27
-47.3
ROA % -98.90
ROSG's ROA % is ranked lower than
89% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. ROSG: -98.90 )
Ranked among companies with meaningful ROA % only.
ROSG' s ROA % Range Over the Past 10 Years
Min: -240.7  Med: -81.02 Max: -40.87
Current: -98.9
-240.7
-40.87
ROC (Joel Greenblatt) % -376.10
ROSG's ROC (Joel Greenblatt) % is ranked lower than
75% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. ROSG: -376.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ROSG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1452.9  Med: -922.18 Max: -202.49
Current: -376.1
-1452.9
-202.49
3-Year Revenue Growth Rate 118.60
ROSG's 3-Year Revenue Growth Rate is ranked higher than
97% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. ROSG: 118.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ROSG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 129.7
Current: 118.6
0
129.7
3-Year EBITDA Growth Rate -18.30
ROSG's 3-Year EBITDA Growth Rate is ranked lower than
80% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ROSG: -18.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ROSG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -27.3 Max: -7.7
Current: -18.3
3-Year EPS without NRI Growth Rate -17.30
ROSG's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. ROSG: -17.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ROSG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.9  Med: -28.5 Max: 45.9
Current: -17.3
-68.9
45.9
GuruFocus has detected 5 Warning Signs with Rosetta Genomics Ltd $ROSG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ROSG's 30-Y Financials

Financials (Next Earnings Date: 2017-09-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:NAS:DRIO, NAS:CHEK » details
Traded in other countries:RQ1.Germany,
Headquarter Location:Israel
Rosetta Genomics Ltd is engaged in the development and commercialization of new diagnostic products based on a recently discovered group of genes known as microRNAs. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA.

Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.

Ratios

vs
industry
vs
history
PB Ratio 0.56
ROSG's PB Ratio is ranked higher than
95% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ROSG: 0.56 )
Ranked among companies with meaningful PB Ratio only.
ROSG' s PB Ratio Range Over the Past 10 Years
Min: 0.46  Med: 2.19 Max: 31.74
Current: 0.56
0.46
31.74
PS Ratio 0.26
ROSG's PS Ratio is ranked higher than
95% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. ROSG: 0.26 )
Ranked among companies with meaningful PS Ratio only.
ROSG' s PS Ratio Range Over the Past 10 Years
Min: 0.26  Med: 27.58 Max: 210.66
Current: 0.26
0.26
210.66
EV-to-EBIT -0.08
ROSG's EV-to-EBIT is ranked lower than
99.99% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ROSG: -0.08 )
Ranked among companies with meaningful EV-to-EBIT only.
ROSG' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.4  Med: -0.5 Max: 0.3
Current: -0.08
-12.4
0.3
EV-to-EBITDA -0.08
ROSG's EV-to-EBITDA is ranked lower than
99.99% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. ROSG: -0.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
ROSG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.4  Med: -0.5 Max: 0.3
Current: -0.08
-12.4
0.3
EV-to-Revenue 0.13
ROSG's EV-to-Revenue is ranked higher than
98% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. ROSG: 0.13 )
Ranked among companies with meaningful EV-to-Revenue only.
ROSG' s EV-to-Revenue Range Over the Past 10 Years
Min: -13.4  Med: 13 Max: 177.3
Current: 0.13
-13.4
177.3
Current Ratio 2.50
ROSG's Current Ratio is ranked lower than
52% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. ROSG: 2.50 )
Ranked among companies with meaningful Current Ratio only.
ROSG' s Current Ratio Range Over the Past 10 Years
Min: 0.65  Med: 6.49 Max: 25.08
Current: 2.5
0.65
25.08
Quick Ratio 2.50
ROSG's Quick Ratio is ranked higher than
54% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. ROSG: 2.50 )
Ranked among companies with meaningful Quick Ratio only.
ROSG' s Quick Ratio Range Over the Past 10 Years
Min: 0.65  Med: 6.49 Max: 25.08
Current: 2.5
0.65
25.08
Days Sales Outstanding 112.69
ROSG's Days Sales Outstanding is ranked lower than
80% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. ROSG: 112.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
ROSG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.47  Med: 136.25 Max: 885.73
Current: 112.69
27.47
885.73
Days Payable 77.23
ROSG's Days Payable is ranked higher than
67% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. ROSG: 77.23 )
Ranked among companies with meaningful Days Payable only.
ROSG' s Days Payable Range Over the Past 10 Years
Min: 62.27  Med: 562.16 Max: 1066.71
Current: 77.23
62.27
1066.71

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.10
ROSG's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. ROSG: -28.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ROSG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -236.2  Med: -88.2 Max: 0
Current: -28.1
-236.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 1.26
ROSG's Price-to-Net-Current-Asset-Value is ranked higher than
95% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. ROSG: 1.26 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ROSG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.34  Med: 1.7 Max: 5.01
Current: 1.26
1.34
5.01
Price-to-Tangible-Book 0.56
ROSG's Price-to-Tangible-Book is ranked higher than
96% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. ROSG: 0.56 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ROSG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.06  Med: 1.57 Max: 3.68
Current: 0.56
1.06
3.68
Price-to-Intrinsic-Value-Projected-FCF 0.68
ROSG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
86% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. ROSG: 0.68 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ROSG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.32  Med: 2.53 Max: 9.04
Current: 0.68
1.32
9.04
Price-to-Median-PS-Value 0.01
ROSG's Price-to-Median-PS-Value is ranked higher than
99% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. ROSG: 0.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ROSG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 0.98 Max: 5.94
Current: 0.01
0.03
5.94
Earnings Yield (Greenblatt) % -1250.00
ROSG's Earnings Yield (Greenblatt) % is ranked lower than
100% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. ROSG: -1250.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ROSG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14035.5  Med: -205.3 Max: 745
Current: -1250
-14035.5
745

More Statistics

Revenue (TTM) (Mil) $9.23
EPS (TTM) $ -9.31
Beta0.36
Short Percentage of Float5.47%
52-Week Range $1.25 - 11.46
Shares Outstanding (Mil)2.64

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 13 18 23
EPS ($) -5.64 -3.96 -2.16
EPS without NRI ($) -5.64 -3.96 -2.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ROSG

Headlines

Articles On GuruFocus.com
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance Nov 18 2014 
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

More From Other Websites
Rosetta Genomics Enters into Agreement to Sell Its PersonalizeDx Business to Pragmin Prognosis Sep 08 2017
Rosetta Genomics Expands Global Patent Protection for RosettaGX Reveal with Patent Allowance in... Sep 06 2017
Rosetta Genomics to Reduce Operating and Other Expenses Sep 05 2017
Major Clinical Reference Laboratory Selects RosettaGX Reveal Thyroid miRNA Classifier as Molecular... Aug 21 2017
Rosetta Genomics Announces Pricing of $2.73 Million Financing Aug 04 2017
Clinical Utility Survey Demonstrates the Potential of RosettaGX Reveal(TM) to Significantly Reduce... Jul 31 2017
RosettaGX Reveal(TM) to be Highlighted in Oral Presentation at the 3rd World Congress on Thyroid... Jul 26 2017
Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China Jul 06 2017
Rosetta Genomics Ltd. :ROSG-US: Earnings Analysis: Q4, 2016 By the Numbers : June 1, 2017 Jun 01 2017
Rosetta Genomics Granted European Patent Allowance Covering RosettaGX Cancer Origin Assay May 25 2017
Rosetta Genomics Enters Collaboration to Develop a microRNA Classifier Relating to Patients with... May 23 2017
Rosetta Genomics Focusing Efforts on Improving Cash Position through Sale of the PersonalizeDx... May 22 2017
Rosetta Genomics Announces Favorable Results from Two Pilot Studies Comparing RosettaGX Reveal(TM)... May 12 2017
Rosetta Genomics Expands International Access for RosettaGX Reveal(TM) through Agreement with... May 05 2017
Rosetta Genomics Receives Final Approval from New York State for First-of-its-kind Thyroid Cancer... May 04 2017
Rosetta Genomics to Increase Investment in RosettaGX Reveal(TM) and Explore Strategic Alternatives... May 02 2017
Rosetta Genomics Expands Patent Portfolio in Europe and Japan May 01 2017
New Data Highlighting the Powerful Performance of RosettaGX Reveal(TM) in Identifying Medullary... Apr 27 2017
Edited Transcript of ROSG earnings conference call or presentation 30-Mar-17 2:00pm GMT Mar 30 2017
Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results Mar 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}